New $NZ 7million Compounding Pharmacy Facility Unveiled

New $NZ 7million Compounding Pharmacy Facility Unveiled

Baxter’s new pharmacy to help secure supply of intravenous chemotherapy, nutrition, and antibiotic products and therapies for the future

Auckland, New Zealand, 27 September 2016

— The Prime Minister of New Zealand the Rt Hon, John Key MP, today officially opened Baxter Healthcare New Zealand’s (Baxter) new $NZ 7million aseptic compounding pharmacy in Mount Wellington. This new industry leading pharmacy will help secure the critical supply of hospital products for New Zealand patients in the North Island.

“For over 30 years we’ve provided lifesaving and life sustaining treatments to the New Zealand people. Our new aseptic compounding pharmacy will increase our production capacity, enabling us to serve North Island patients well into the future,” said Steven Flynn, General Manager for Baxter, Australia and New Zealand.

Baxter is a major supplier of aseptic compounded pharmaceuticals to around 60 public and private hospitals in the North Island of New Zealand. The new pharmacy replaces the current facility that has been in operation since 1982, and will provide patients with over 200,000 units of chemotherapy, nutrition products and antibiotic therapies each year. Baxter’s supply of patient specific antibiotics and nutritional solutions in ready to use formats also allows people to undertake treatment at home.

“We’re committed to making sure patients in New Zealand have continuous access to critical therapies. The new facility and increased capacity will also act in conjunction with our pharmacy in Christchurch as an important contingency for patients and hospitals across New Zealand in times of national emergencies,” Mr Flynn said.

This ongoing investment demonstrates Baxter’s long term commitment and confidence in the New Zealand economy and health care system. Baxter proudly employs 140 people across New Zealand and contributes $77M to the NZ GDP1.

In August 2016, the American Chamber of Commerce in New Zealand recognised Baxter as the Investor of the Year in its annual awards. The Awards focus on identifying and celebrating success and innovation in New Zealand, and was presented to Baxter for its investment in the New Zealand health sector with the construction of this new aseptic compounding facility.

ends

© Scoop Media